Панипенем

Panipenem is a broad spectrum carbapenem antibacterial and antimicrobial agent working against Gram-negative and Gram-positive organisms.

A 3-acetimidoylpyrrolidinyl-substituted carbapenem with no methyl group at the C-1 position. It has broad-spectrum antibacterial activity against Gram-positive and Gramnegative organisms very similar to that of other carbapenems. Activity against Ps. aeruginosa is similar to that of imipenem. It is co-administered in a ratio of 1:1 with betamipron (N-benzoyl-β-alanine), a renal anion transport inhibitor that decreases nephrotoxicity. Panipenem is slightly more stable to hydrolysis by dehydropeptidase than imipenem, but not as stable as meropenem or biapenem. It is hydrolyzed by carbapenemases.
Mean maximum blood concentrations following intravenous infusion of 0.5 g and 0.75 g of each component were 37 and 61 mg/L for panipenem and 24 and 39 mg/L for betamipron. Following intravenous infusion in children (10 mg or 20 mg of each component per kg), the half-life of panipenem was about 1.2 h; that of betamipron about 0.9 h. Drug levels in the CSF were at least eight-fold lower than serum concentrations.
Side effects are similar to those reported for other carbapenems (incidence <10%) and are generally mild. Patients with a history of previous hypersensitivity reactions to penicillins, cephalosporins or other β-lactam antibiotics should be treated cautiously.
Clinical use in serious infections is similar to that of other carbapenems.